Imaging studies offer the potential for non-invasive detection of key molecules that are important in prostatecancer biology and medicine. The goal of the Small Animal Imaging Core is to provide imaging researchsupport to investigators who are involved in defining a prostate cancer signature, often at the molecularlevel. Imaging studies may serve as a non-invasive phenotypic correlate of the molecular changes. Theprimary responsibility of the Small Animal Imaging Core will be to provide positron emission tomography(PET), Single Photon Emission Computed Tomography (SPECT), optical, and magnetic resonance imagingand spectroscopy capability at the highest spatial resolution possible to monitor the effect of molecularchanges and for the study of cancer biology in animal models. Available instrumentation include 2 magneticresonance imaging/spectroscopy systems (4.7T/40 cm bore and 7.0T/31 cm bore systems), 2 MIcroPETsystems, MicroCT, MicroSPECT, and optical imaging equipment (IVIS) for fluorescence andbioluminescence imaging. Achievements of the Small Animal Imaging Core during the last interval include14 publications and 2 grants directly related to small animal imaging based on SPORE funded research.Based on our previous experience, a significant portion of the imaging research performed will focus onobtaining high resolution anatomic imaging. The goals of these studies will be to detect tumor at minimalburden, characterize growth rates, and monitor response to novel therapies. Some of these studies (RP4)may utilize novel imaging schemes such as imaging 3'-deoxy-3'-(18)F-fluorothymidine (FLT) as aproliferation marker, MR spectroscopic measurements of proliferation (and correlate the PET and MR datawith each other and Ki67 measurements), and dynamic contrast enhanced MRI to evaluate antiangiogenesisagents. In addition, we will evaluate different PET radionuclide tracers as potential imagingagents including 11C-methionine, 18F-fluorodeoxyglucose, 18F-fluorodihydrotestosterone and 1241-iododeoxyuridine) which will be correlated with pathologic data. A major emphasis will be to assure aphysiologically appropriate environment during imaging studies (temperature control, heart and respiratoryrate). Construction of a radiofrequency resonator designed to image multiple mice simultaneously withinhalation anesthesia, temperature monitoring etc. will be done. To enhance spatial resolution, moresensitive resonators coils will be investigated. As a core facility, the main goal will be to provide state of theart imaging capability, improvements in image processing and analysis to enhance the accuracy of multimodalityimaging (supported in collaboration with other grants), and appropriate radiotracers which will beprovided by the Cyclotron and Radiochemistry Core of Memorial Sloan Kettering Cancer Center

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA092629-06
Application #
7147044
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2005-09-26
Project End
2011-06-30
Budget Start
2005-09-26
Budget End
2007-08-31
Support Year
6
Fiscal Year
2006
Total Cost
$65,821
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Lee, Justin K; Sjoberg, Daniel D; Miller, Mariam Imnadze et al. (2018) Improved Recovery of Erectile Function in Younger Men after Radical Prostatectomy: Does it Justify Immediate Surgery in Low-risk Patients? Eur Urol 73:33-37
Capogrosso, Paolo; Vertosick, Emily A; Benfante, Nicole E et al. (2018) Are We Improving Erectile Function Recovery After Radical Prostatectomy? Analysis of Patients Treated over the Last Decade. Eur Urol :
Heller, Glenn; McCormack, Robert; Kheoh, Thian et al. (2018) Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. J Clin Oncol 36:572-580
Autio, Karen A; Dreicer, Robert; Anderson, Justine et al. (2018) Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA Oncol 4:1344-1351
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Abida, Wassim; Sawyers, Charles L (2018) Targeting DNA Repair in Prostate Cancer. J Clin Oncol 36:1017-1019
Kaittanis, Charalambos; Andreou, Chrysafis; Hieronymus, Haley et al. (2018) Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J Exp Med 215:159-175
Moore, Amanda R; Ran, Leili; Guan, Youxin et al. (2018) GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Rep 22:2455-2468
Carlsson, Sigrid V; Lilja, Hans (2018) Perspective on Prostate Cancer Screening. Clin Chem :
Puca, Loredana; Bareja, Rohan; Prandi, Davide et al. (2018) Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun 9:2404

Showing the most recent 10 out of 505 publications